139 related articles for article (PubMed ID: 38706697)
1. The prophylactic antiemetic therapies in management of differentiated thyroid cancer patients with radioactive iodine therapy: a single-center, non-randomized clinical trial.
Li X; Cao J; Wang W; Zhu X; Sun Y; Song L; Zhang W; Han Y
Front Endocrinol (Lausanne); 2024; 15():1310223. PubMed ID: 38706697
[TBL] [Abstract][Full Text] [Related]
2. Management of gastrointestinal complaints in differentiated thyroid cancer patients treated with (131)I: comparison of the efficacy of pantoprazole, metoclopramide, and ondansetron - a randomized clinical trial.
Mirzababaee M; Shafiei B; Seifollahi S; Motazdian M; Fatholahi L; Delavari S; Naghshine R; Baharfar N; Tabeie F; Javadi H; Assadi M; Asli IN
Nuklearmedizin; 2014; 53(5):186-9. PubMed ID: 24961816
[TBL] [Abstract][Full Text] [Related]
3. Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron.
Ikeoka T; Ando T; Imaizumi M; Ueki I; Usa T; Kawakami A
Endocrine; 2014 May; 46(1):131-7. PubMed ID: 24078409
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.
Ithimakin S; Runglodvatana K; Nimmannit A; Akewanlop C; Srimuninnimit V; Keerativitayanan N; Soparattanapaisarn N; Laocharoenkeat A
Support Care Cancer; 2012 Apr; 20(4):849-55. PubMed ID: 21505898
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma.
Kamiya T; Sakurai M; Kikuchi T; Okayama M; Mizuno K; Tanigawa T; Koda Y; Kato J; Mori T
Hematology; 2021 Dec; 26(1):945-949. PubMed ID: 34789076
[TBL] [Abstract][Full Text] [Related]
6. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
Jeremić B
Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
[TBL] [Abstract][Full Text] [Related]
7. Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT.
Robson S; McParlin C; Mossop H; Lie M; Fernandez-Garcia C; Howel D; Graham R; Ternent L; Steel A; Goudie N; Nadeem A; Phillipson J; Shehmar M; Simpson N; Tuffnell D; Campbell I; Williams R; O'Hara ME; McColl E; Nelson-Piercy C
Health Technol Assess; 2021 Nov; 25(63):1-116. PubMed ID: 34782054
[TBL] [Abstract][Full Text] [Related]
8. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.
Lebeau B; Depierre A; Giovannini M; Rivière A; Kaluzinski L; Votan B; Hédouin M; d'Allens H
Ann Oncol; 1997 Sep; 8(9):887-92. PubMed ID: 9358940
[TBL] [Abstract][Full Text] [Related]
10. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Berry WR; House KW; Lee JT; Plagge PB; Meshad MW; Grapski R
Semin Oncol; 1992 Dec; 19(6 Suppl 15):33-7. PubMed ID: 1485180
[TBL] [Abstract][Full Text] [Related]
11. Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.
Gridelli C; Haiderali AM; Russo MW; Blackburn LM; Lykopoulos K
Support Care Cancer; 2010 Nov; 18(11):1437-44. PubMed ID: 19882176
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups.
Fortney JT; Gan TJ; Graczyk S; Wetchler B; Melson T; Khalil S; McKenzie R; Parrillo S; Glass PS; Moote C; Wermeling D; Parasuraman TV; Duncan B; Creed MR
Anesth Analg; 1998 Apr; 86(4):731-8. PubMed ID: 9539593
[TBL] [Abstract][Full Text] [Related]
14. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy.
Sykes AJ; Kiltie AE; Stewart AL
Support Care Cancer; 1997 Nov; 5(6):500-3. PubMed ID: 9406364
[TBL] [Abstract][Full Text] [Related]
15. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia.
Ascaso FJ; Ayala I; Carbonell P; Castro FJ; Palomar A
Ophthalmologica; 1997; 211(5):292-5. PubMed ID: 9286804
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
18. Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial.
Ruktrirong J; Traivaree C; Monsereenusorn C; Photia A; Lertvivatpong N; Rujkijyanont P
Pediatr Blood Cancer; 2021 Jun; 68(6):e29002. PubMed ID: 33754455
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
20. Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery.
Krobbuaban B; Pitakpol S; Diregpoke S
J Med Assoc Thai; 2008 May; 91(5):669-74. PubMed ID: 18672630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
